Lotus Eye Hospital and Institute Limited

NSEI:LOTUSEYE Voorraadrapport

Marktkapitalisatie: ₹1.7b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Lotus Eye Hospital and Institute Beheer

Beheer criteriumcontroles 4/4

De CEO Lotus Eye Hospital and Institute's is Kuttapalayam Ramalingam, benoemd in Aug2020, heeft een ambtstermijn van 4.17 jaar. bezit rechtstreeks 1.43% van de aandelen van het bedrijf, ter waarde ₹ 24.58M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.1 jaar en 4.8 jaar.

Belangrijke informatie

Kuttapalayam Ramalingam

Algemeen directeur

₹1.2m

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO4.2yrs
Eigendom CEO1.4%
Management gemiddelde ambtstermijn4.1yrs
Gemiddelde ambtstermijn bestuur4.8yrs

Recente managementupdates

Recent updates

Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking

Aug 21
Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking

Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Jan 24
Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 08
Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Jul 15
We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

Apr 07
Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Oct 08
We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 02
Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

Jun 17
If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Mar 11
MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Dec 30
Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

Nov 20
Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

Sep 21
The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

Aug 27
Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Aug 03
Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

Jul 06
Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

CEO

Kuttapalayam Ramalingam (74 yo)

4.2yrs

Tenure

₹1,200,000

Compensatie

Dr. Kuttapalayam Songappan Ramalingam, M.D., serves as an Executive Director at Lotus Eye Hospital and Institute Limited since February 10, 2021. Dr. Ramalingam serves as Chief Executive Officer at Lotus E...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Kuttapalayam Ramalingam
CEO & Executive Director4.2yrs₹1.20m1.43%
₹ 24.6m
Ramanujam Reghunathan
Chief Financial Officer2.4yrs₹1.70mgeen gegevens
Mohanmenon Menon
Company Secretary & Compliance Officer2.7yrs₹1.08mgeen gegevens
Sangeetha Sundaramoorthy
MD & Director4.1yrs₹3.09m18.84%
₹ 322.8m
Rajkumar Sundaramoorthy
Vice President of Administration6.4yrsgeen gegevens0.21%
₹ 3.5m

4.1yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van LOTUSEYE wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Kuttapalayam Ramalingam
CEO & Executive Director3.7yrs₹1.20m1.43%
₹ 24.6m
Sangeetha Sundaramoorthy
MD & Director4.9yrs₹3.09m18.84%
₹ 322.8m
Rajkumar Sundaramoorthy
Vice President of Administration4.8yrsgeen gegevens0.21%
₹ 3.5m
Devarayapuram Kaarthikeyan
Non-Executive Independent Director17yrs₹200.00kgeen gegevens
Kavetha Sundaramoorthy
Chairman of the Board8.4yrs₹150.00k18.78%
₹ 321.8m
Yogesh Shah
Non-Executive Independent Director17yrs₹200.00kgeen gegevens
Marappa Alagiriswamy
Non-Executive Independent Director12.4yrs₹200.00kgeen gegevens
Sengodagounder Natesan
Independent Director3.8yrs₹200.00kgeen gegevens
Gopalakrishnan Veeramani
Independent Non-Executive Director1.8yrs₹200.00kgeen gegevens
Perumalsamy Mahendran
Independent Non-Executive Director1.7yrs₹175.00kgeen gegevens

4.8yrs

Gemiddelde duur

75yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van LOTUSEYE wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).